The company sources raw materials, including active pharmaceutical ingredients and fixed assets, to manufacture ARIKAYCE, with an estimated investment of approximately $127.7 million aimed at increasing long-term production capacity. It has a commercialization agreement with PARI, the manufacturer of the drug delivery nebulizer for ARIKAYCE. In January 2024, the company entered into agreements with Patheon Inc., a subsidiary of Thermo Fisher, for the manufacture and supply of commercial brensocatib products, including BRINSUPRI. In September 2024, it established a commercial manufacturing and supply agreement with Esteve Química, S.A. for the production and supply of the active pharmaceutical ingredient for brensocatib. The company is responsible for delivering the active pharmaceutical ingredient to Patheon Inc. for BRINSUPRI manufacturing and plans to use contract manufacturing organizations for future TPIP manufacturing needs while evaluating in-house manufacturing capabilities.
Insmed Inc's Comment on Supply Chain
The company sources raw materials, including active pharmaceutical ingredients and fixed assets, to manufacture ARIKAYCE, with an estimated investment of approximately $127.7 million aimed at increasing long-term production capacity. It has a commercialization agreement with PARI, the manufacturer of the drug delivery nebulizer for ARIKAYCE. In January 2024, the company entered into agreements with Patheon Inc., a subsidiary of Thermo Fisher, for the manufacture and supply of commercial brensocatib products, including BRINSUPRI. In September 2024, it established a commercial manufacturing and supply agreement with Esteve Química, S.A. for the production and supply of the active pharmaceutical ingredient for brensocatib. The company is responsible for delivering the active pharmaceutical ingredient to Patheon Inc. for BRINSUPRI manufacturing and plans to use contract manufacturing organizations for future TPIP manufacturing needs while evaluating in-house manufacturing capabilities.
Sources:
Insmed Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Insmed Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
